The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLI.e

ARDS - Acute lung injury

The role of G/GM CSF in promotig bleomycin pulmonary toxicity is unclear (PMID 30319063)

Publications

Doig C, Cooke R, Chua C, Leung T

Acute respiratory distress syndrome precipitated by granulocyte colony-stimulating factor in undiagnosed pneumonia.

BMJ case reports 2022 Feb 03;15; — 2022 Feb 03

Shalata W, Waichenberg L, Massalha I, Dudnik Y, Rouvinov K, Yakobson A

Pulmonary toxicity following administration of granulocyte colony-stimulating factor during chemotherapy for breast cancer: a case report and literature review.

Anti-cancer drugs 2021 Jul 04;; — 2021 Jul 04

Kudlak K, Demuro JP, Hanna AF, Brem H

Acute lung injury following the use of granulocyte-macrophage colony-stimulating factor.

International journal of critical illness and injury science 2013 Oct;3;279-81 — 2013 Oct — 279-81

Wetzko K, Blechschmidt M, Hölig K, Poppe-Thiede K, Ganepola S, Fischbach R, Ordemann R, Laniado M, Schulte-Hubbert B, Schuler M, Cotta L, Braumann D, Ehninger G, Kroschinsky F

Pulmonary adverse events in unrelated donors of peripheral blood stem cells.

Transfusion medicine (Oxford, England) 2013 Feb;23;69-71 — 2013 Feb — 69-71

Shi B, Liu L, Ye L

Lung injury in a leukemia patient during mobilization of peripheral blood stem cells using granulocyte colony-stimulating factor alone.

Annals of hematology 2012 Mar;91;469-70 — 2012 Mar — 469-70

Halter J, Kodera Y, Ispizua AU, Greinix HT, Schmitz N, Favre G, Baldomero H, Niederwieser D, Apperley JF, Gratwohl A

Severe events in donors after allogeneic hematopoietic stem cell donation.

Haematologica 2009 Jan;94;94-101 — 2009 Jan — 94-101

Takatsuka H, Takemoto Y, Mori A, Okamoto T, Kanamaru A, Kakishita E

Common features in the onset of ARDS after administration of granulocyte colony-stimulating factor.

Chest 2002 May;121;1716-20 — 2002 May — 1716-20

Azoulay E, Attalah H, Harf A, Schlemmer B, Delclaux C

Granulocyte colony-stimulating factor or neutrophil-induced pulmonary toxicity: myth or reality? Systematic review of clinical case reports and experimental data.

Chest 2001 Nov;120;1695-701 — 2001 Nov — 1695-701

Couderc LJ, Stelianides S, Frachon I, Stern M, Epardeau B, Baumelou E, Caubarrere I, Hermine O

Pulmonary toxicity of chemotherapy and G/GM-CSF: a report of five cases.

Respiratory medicine 1999 Jan;93;65-8 — 1999 Jan — 65-8

Verhoef G, Boogaerts M

Treatment with granulocyte-macrophage colony stimulating factor and the adult respiratory distress syndrome.

American journal of hematology 1991 Apr;36;285-7 — 1991 Apr — 285-7

Miniero R, Madon E, Artesani L, Busca A, Sandri A, Aglietta M, Ramenghi U

Acute pulmonary failure after the first administration of recombinant human granulocyte-macrophage colony-stimulating factor.

Leukemia 1992 Apr;6;352-3 — 1992 Apr — 352-3